At 8.7% CAGR, the North America Home Infusion Therapy Market is projected to be worth US$ 18,112.18 Million by 2028, says Business Market Insights

According to Business Market Insights’ research, the North America home infusion therapy market was valued at US$ 10,954.08 million in 2022 and is expected to reach US$ 18,112.18 million by 2028, registering a CAGR of 8.7% from 2022 to 2028. Reduction in duration of hospital stays and cost of care and increasing incidences of chronic disorders coupled with rising geriatric population are the critical factors attributed to the North America home infusion therapy market expansion.

Many times, patients need to stay in the hospital to complete their course of intravenous drug administrations before they are shifted to oral medications. However, with an effective home infusion service, these patients can be transitioned to home early. The hospital-at-home model delivers hospital-level care within the home environment to support improved outcomes and enhance the patient experience. Thus, the possibility to treat several complicated medical conditions with home infusion therapies help reduce the length of hospital stays, consequently reducing the cost of treatment.

According to the National Home Infusion Association (NHIA), 3.2 million patients receive home infusion every year, and 98% of these admitted are being “very satisfied” with their treatment. According to a study by the NHIA in 2019, home infusion and specialty providers in the US served ~3 million patients in 2019, reporting a 300% increase in their sales in the last decade. Home infusion imparts significant cost-savings compared to a traditional hospital infusion setting. Infusion provided at home costs 50% less than infusion provided at hospital facilities. According to the article published by Beckers Hospital in 2020, the average cost of home infusion is US$ 140–250 per day while hospital infusions on average costs US$ 590 per patient per infusion. According to the Commonwealth Fund, hospital-at-home programs help to cut the cost of care by over 30%, doing remarkably well in countries with single-payer systems, such as Canada.

Patients requiring intravenous therapies in emergency departments can be shifted to home infusion after clinical assessment. The homecare plan includes robust clinical monitoring at home, which allows the early identification of further clinical problems and the implementation of treatment plans to avoid readmissions. An Option Care study of 124 home parenteral nutrition (HPN) and 126 home enteral nutrition (HEN) patients showed that home infusion prevents hospitalization and improves patient care. Both HPN and HEN therapies can be temporarily administered in hospitals, yet ~40,000 HPN patients and 344,000 HEN patients yearly receive their nutrition therapies at home. Therefore, a significant reduction in the cost of care with a decrease in the length of hospital stays, along with the increasing number of patients availing homecare services, fuel the home infusion therapy market growth.

On the contrary, recalls of infusion pumps and safety concerns associated with home infusion hurdles the growth of North America home infusion therapy market.

Based on product, the home infusion therapy market is segmented into infusion pumps, intravenous sets, IV cannulas, and needleless connectors. The home infusion therapy market segment is sub segmented into insulin pumps, elastomeric pumps, syringe pumps, and others. The infusion pumps segment held 55.7% market share in 2022, amassing US$ 6,100.08 million. It is projected to garner US$ 10,266.56 million by 2028 to expand at 9.1% CAGR during 2022–2028.  

Based on application, the home infusion therapy market is segmented into enteral nutrition, anti-infective, endocrinology, hydration therapy, chemotherapy, specialty pharmaceuticals, and others. The anti-infective segment held 25.1% market share in 2022, amassing US$ 2,745.17 million. It is projected to garner US$ 4,551.14 million by 2028 to expand at 8.8% CAGR during 2022–2028.    

Based on route of administration, the home infusion therapy market is segmented into intramuscular, subcutaneously, and epidural. The intramuscular segment held 75.9% market share in 2022, amassing US$ 8,315.08 million. It is projected to garner US$ 13,926.28 million by 2028 to expand at 9.0% CAGR during 2022–2028.    

Based on country, the North America home infusion therapy market is segmented into the US, Canada, and Mexico. Our regional analysis states that the US captured 83.6% market share in 2022. It was assessed at US$ 9,153.85 million in 2022 and is likely to hit US$ 15,272.19 million by 2028, exhibiting a CAGR of 8.9% during the forecast period.

Key players dominating the North America home infusion therapy market are B. Braun Melsungen AG; Baxter International Inc; Nipro Corp; Becton Dickinson and Co; Fresenius Kabi AG; ICU Medical Inc; JMS Co Ltd; Eitan Medical Ltd; Terumo Corp, among others.      

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com